Candid stewardship of one big open question: management engages seriously with a consequential unresolved outcome
The model's full reasoning — Q4 2023 call → NOThe question asks whether management identifies and seriously engages with one consequential operational outcome that is still unresolved — a specific undertaking already in motion whose result is not yet known — and discusses it with visible candor and operational specificity. Looking at the transcript, management discusses several things: 1. New product launches in 2024 (back-weighted, lower contribution than 2023) 2. Distributor rationalization (closing accounts with diversion evidence) 3. Marketing investments and initiatives 4. The overall turnaround strategy The most concrete "undertaking in motion" appears to be the distributor rationalization and the new product launches. Let me examine whether management treats these as genuinely open with candor and operational specificity. For distributor rationalization: Eric Tiziani says "we plan to rationalize certain distributors and accounts that do not build brand equity either due to off-strategy pricing for sub distribution into unauthorized resellers. We are using various methods, including our track and trace technology, third-party experts, and other anti-diversion and anti-counterfeiting measures to specifically target the distributor rationalization. We've already made good progress here in the second half of 2023, so we're planning to continue those efforts." This is somewhat specific — they describe methods and progress. For new product launches: Amanda says "we anticipate incremental sales contribution from new product launches this year, but expect the contribution from new products in 2024 to be lower than in 2023 given the timing of key launches starting later this year." This is fairly vague — no specific products, no specific progress details. The question asks for ONE consequential operational outcome that is still unresolved, discussed with candor and operational specificity — what's going well, what's not yet proven, what they're doing now, what would make it succeed or fall short. Looking at the overall discussion, management does acknowledge uncertainty — "we're taking a long-term view" and "this journey will take some time." But the specific undertakings discussed (new product launches, distributor rationalization) are not discussed with the level of operational specificity required — no details on what's going well vs. not proven, no specifics on what would make them succeed or fail.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MCD | McDonald's Corporation | Q2 2024 | 2024-07-29 | D |
| MMLP | Martin Midstream Partners L.P. | Q2 2024 | 2024-07-18 | B |
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| CTRA | Coterra Energy Inc. | Q1 2024 | 2024-05-03 | A |
| SNV | Synovus Financial Corp. | Q1 2024 | 2024-04-18 | B |
| CLGN | CollPlant Biotechnologies Ltd. | Q4 2023 | 2024-04-04 | F |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| KMDA | Kamada Ltd. | Q2 2023 | 2023-08-16 | B+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ORGO | Organogenesis Holdings Inc. | Q4 2022 | 2023-03-01 | C |
| TWLO | Twilio Inc. | Q4 2022 | 2023-02-15 | D |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| REGN | Regeneron Pharmaceuticals, Inc. | Q4 2022 | 2023-02-03 | C |
| CUE | Cue Biopharma, Inc. | Q3 2022 | 2022-11-14 | D |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| ASTS | AST SpaceMobile, Inc. | Q2 2022 | 2022-08-15 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| CDXC | ChromaDex Corporation | Q4 2021 | 2022-03-09 | C+ |
| VNDA | Vanda Pharmaceuticals Inc. | Q4 2021 | 2022-02-23 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| MOMO | Hello Group Inc. | Q3 2021 | 2021-11-30 | D |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| AKBA | Akebia Therapeutics, Inc. | Q3 2021 | 2021-11-09 | C+ |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| AX | Axos Financial, Inc. | Q4 2021 | 2021-07-29 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| UAA | Under Armour, Inc. | Q3 2017 | 2017-10-31 | F |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DHX | DHI Group, Inc. | Q2 2017 | 2017-07-28 | D |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| TPB | Turning Point Brands, Inc. | Q1 2017 | 2017-05-11 | B |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| MRIN | Marin Software Incorporated | Q4 2016 | 2017-02-28 | D |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| FIBK | First Interstate BancSystem, Inc. | Q4 2016 | 2017-01-27 | B+ |
| SUPN | Supernus Pharmaceuticals, Inc. | Q3 2016 | 2016-11-18 | D |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| SOHO | Sotherly Hotels Inc. | Q3 2016 | 2016-11-08 | D |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| CHDN | Churchill Downs Incorporated | Q2 2016 | 2016-08-04 | C+ |
| CRIS | Curis, Inc. | Q1 2016 | 2016-05-09 | C |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
TACT · Q4 2022 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED... YES The transcript shows management seriously engaging with the large QSR rollout as a specific, already-in-motion undertaking whose outcome remains open. Bart describes it as an ongoing testing and implementation process that has taken over two years, with the company expecting it to begin rolling out in the second half of 2023 (mid-to end of Q3 through Q4) if testing succeeds. He notes recent new orders coming in during Q1, acknowledges the process has had “starts and stops,” and frames success around whether testing goes right and whether the pipeline continues to convert. Steve adds that the rollout will drive significant FST growth in 2024 2023. This is treated as genuinely uncertain rather than assured, with concrete operational details on current progress (new orders, testing), remaining risks (testing outcome, integration), and actions being taken (staying close to the customer, filling the pipeline).
FLUX · Q2 2022 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED... YES The transcript shows management actively engaging with the unresolved outcome of scaling production to fulfill the record $31.4 million backlog while restoring gross margins, a specific undertaking already in motion through lean manufacturing, second-shift ramp (launching this month), Mexico sourcing, design cost reductions, and aggressive supplier negotiations. They describe concrete progress (weekly orders, production throughput improvements, quality initiatives) alongside acknowledged risks (chip and component shortages, delayed price effects, inventory commitments), explain current actions (vendor metrics, alternate suppliers, ERP changes), and outline success factors (higher-margin large-pack mix, reduced overstocking).
UAA · Q3 2017 → YESThe question is: Does management identify and seriously engage with ONE CONSEQUENTIAL OPERATIONAL OUTCOME THAT IS STILL UNRESOLVED — a specific, identifiable thing already in motion... whose result is...YES The transcript shows management identifying the ERP system implementation (launched July 1) as a specific, already-in-motion operational outcome whose result remains unresolved. They detail concrete progress (system now stable, service levels improving) and current actions (ongoing change management with vendors and workforce, fine-tuning through Q4 into 2018), while openly noting residual impacts on shipments and productivity that will not fully resolve until later in the year. This is framed as a genuine risk to Q4 and full-year results rather than a guaranteed success, with visible operational specificity on what is working and what remains unproven.